SUTENT is indicated for the treatment of:
- Advanced renal cell carcinoma (RCC)
- Gastrointestinal stromal tumor (GIST) after disease progression
on or intolerance to imatinib mesylate
|
Now available: Journal of Clinical Oncology reprint on overall survival (OS) with sunitinib versus interferon alfa (IFNα) as first-line treatment of metastatic renal cell carcinoma (mRCC). Access the reprint now.
Median OS has been reached in the phase 3 study comparing sunitinib with IFNα in the first-line treatment of mRCC.1 See the OS data now.
Watch Dr Christopher Ryan discuss how SUTENT inhibits tumor progression. View the video now.
|
|
Patients can call 1-877-5-SUTENT Monday through Friday from 8 AM To 7 PM CT to speak
to trained oncology nurses. The nurses do not provide medical advice, but reinforce
general information about SUTENT, including:
- Potential side effects
- Treatment information
- RCC and GIST information
View the patient call
center brochure.
|
Reference:
1. Data on file. Pfizer Inc, New York, NY.